Neoadjuvant treatment with Bevacizumab and folfox-6 in patients with liver metastasis from colorectal cancer: Preliminary results of a phase II study

被引：0
|
作者：
Bertolini, F. [1 ]
Malavasi, N. [1 ]
Dealis, C. [1 ]
Zroni, S. [1 ]
Depenni, R. [1 ]
Fontana, A. [1 ]
Sternieri, R. [1 ]
Ponti, G. [1 ]
Luppi, G. [1 ]
Conte, P. [1 ]
机构：
[1] Univ Modena & Reggio Emilia, Modena, Italy
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [31] Early Results of Phase II Trial of Neoadjuvant Chemotherapy with S-1 and Oxaliplatin Plus Bevacizumab for Colorectal Liver Metastasis
    Uehara, K.
    Goto, H.
    Hiramatsu, K.
    Kobayashi, S.
    Sakamoto, E.
    Maeda, A.
    Takeuchi, E.
    Okada, Y.
    Tojima, Y.
    Yamamoto, R.
    Okamoto, Y.
    Nagino, M.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S74 - S74
  • [32] Neoadjuvant chemotherapy with atezolizumab, bevacizumab, and FOLFOX for patients with unresectable colorectal liver metastases: A translational pilot study
    Kim, Sun Young
    Kim, Wonkyung
    Sung, Chang Ohk
    Kim, Jihun
    Hong, Yong Sang
    Kim, Jeong Eun
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] QUALITY OF LIFE OF PATIENTS WITH METASTATIC COLORECTAL CANCER RECEIVING EITHER XELOX OR FOLFOX-6 REGIMEN: A RANDOMIZED PHASE III STUDY
    Conroy, T.
    Hebbar, M.
    Bennouna, J.
    Ducreux, M.
    Ychou, M.
    Lledo, G.
    Adenis, A.
    Faroux, R.
    Rebischung, C.
    Kockler, L.
    Douillard, J. Y.
    ANNALS OF ONCOLOGY, 2009, 20 : 13 - 13
  • [34] DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
    J P B O'Connor
    C J Rose
    A Jackson
    Y Watson
    S Cheung
    F Maders
    B J Whitcher
    C Roberts
    G A Buonaccorsi
    G Thompson
    A R Clamp
    G C Jayson
    G J M Parker
    British Journal of Cancer, 2011, 105 : 139 - 145
  • [35] Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with, metastastic colorectal cancer
    Meyerhardt, J. A.
    Stuart, K.
    Fuchs, C. S.
    Zhu, A. X.
    Earle, C. C.
    Bhargava, P.
    Blaszkowsky, L.
    Enzinger, P.
    Mayer, R. J.
    Battu, S.
    Lawrence, C.
    Ryan, D. P.
    ANNALS OF ONCOLOGY, 2007, 18 (07) : 1185 - 1189
  • [36] A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer
    Okita, Natsuko T.
    Esaki, Taito
    Baba, Eishi
    Sakai, Daisuke
    Tokunaga, Shinya
    Takiuchi, Hiroya
    Mizunuma, Nobuyuki
    Nagashima, Kengo
    Kato, Ken
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 2026 - 2031
  • [37] A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer
    Natsuko T. Okita
    Taito Esaki
    Eishi Baba
    Daisuke Sakai
    Shinya Tokunaga
    Hiroya Takiuchi
    Nobuyuki Mizunuma
    Kengo Nagashima
    Ken Kato
    Investigational New Drugs, 2012, 30 : 2026 - 2031
  • [38] Predictive role of fluorodeoxyglucose positron emission tomography (18 fF-FDG CT-PET) in early assessment of response to bevacizumab and FOLFOX-6 combined neoadjuvant therapy for liver metastasis (LM) from colorectal cancer (CRC)
    Malavasi, N.
    Bagni, B.
    Bertolini, F.
    Dealis, C.
    Depenni, R.
    Cucca, M.
    Casolo, A.
    Ponti, G.
    Luppi, G.
    Conte, P. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
    O'Connor, J. P. B.
    Rose, C. J.
    Jackson, A.
    Watson, Y.
    Cheung, S.
    Maders, F.
    Whitcher, B. J.
    Roberts, C.
    Buonaccorsi, G. A.
    Thompson, G.
    Clamp, A. R.
    Jayson, G. C.
    Parker, G. J. M.
    BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 139 - 145
  • [40] Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
    Barve, Vedin
    Adams, Ned
    Stanbery, Laura
    Manning, Luisa
    Horvath, Staci
    Wallraven, Gladice
    Bognar, Ernest
    Barve, Minal
    Nemunaitis, John
    VACCINES, 2021, 9 (10)
12345